2024-10-17 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis

**1. Performance Comparison**

Eli Lilly and Co (LLY) has significantly outperformed the S&P 500 (VOO) with a cumulative return of 879.78% compared to the S&P 500's 135.94%. This translates to a massive gap of 743.84%, placing LLY at the 92.31 percentile of its historical performance relative to the S&P 500. This indicates that LLY has historically been a strong performer compared to the broader market.

**Eli Lilly and Co** is a pharmaceutical company that develops and markets a wide range of prescription drugs, including treatments for diabetes, cancer, and autoimmune diseases.

**2. Recent Price Action**

* **Closing Price:** 913.32
* **5-day Moving Average:** 920.64 
* **20-day Moving Average:** 906.92 
* **60-day Moving Average:** 896.97

LLY is currently trading slightly below its 5-day moving average, suggesting a slight short-term downward pressure. However, it remains above its 20 and 60-day moving averages, indicating a positive trend in the medium to long-term.

**3. Technical Indicators**

* **RSI:** 46.28 - This indicates that LLY is currently neither overbought nor oversold, suggesting potential for both upward and downward movement.
* **PPO:** 0.32 - A positive PPO value indicates a bullish momentum.
* **Delta_Previous_Relative_Divergence:** -0.28 - This indicates a short-term downward trend in the relative strength of LLY compared to the S&P 500.
* **Expected Return:** 36.58% - This represents the potential maximum 5-year expected return for LLY over the S&P 500, based on current investment.

**4. Recent Earnings and Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2023-05-09 | 1.96 | 8.31 B$ |

LLY's recent earnings have shown consistent growth, surpassing analyst expectations in the latest quarter (2024-08-08) with an EPS of 3.29, exceeding the anticipated 3.25. This positive earnings performance demonstrates the company's continued strong financial performance and growth trajectory. 

**5. News and Recent Issues**

**Recent Market Outlook:** 

* **FINBOLD:** Analysists are generally optimistic about LLY's future, citing strong drug pipeline and strong earnings reports.
* **Seeking Alpha:** LLY is praised for its consistent revenue growth and its strong position in the pharmaceutical market.

**Analyst Opinions:**

* **Morgan Stanley:**  Maintains an "Overweight" rating with a price target of $1,050, citing strong growth prospects for LLY's new drug launches.
* **J.P. Morgan:**  Maintains an "Overweight" rating with a price target of $1,000, highlighting LLY's robust pipeline of promising drug candidates.

**Performance Highlights:**

* LLY has seen strong performance in recent years, driven by its successful new drug launches and increasing market share.
* LLY's strong financial performance and growth potential make it an attractive investment for long-term investors.

**6. Comprehensive Analysis**

LLY has consistently outperformed the market, with a strong history of delivering robust earnings and growth. The company's focus on innovation and its deep pipeline of potential blockbuster drugs contribute to its positive outlook. The current market outlook remains positive, with analysts predicting continued growth and strong performance. While some recent technical indicators suggest a potential short-term pullback, LLY's fundamental strength and long-term growth prospects make it a compelling investment opportunity for investors seeking exposure to the healthcare sector.

**7. English Report**

## Eli Lilly and Co (LLY) Stock Analysis

**1. Performance Comparison**

Eli Lilly and Co (LLY) has significantly outperformed the S&P 500 (VOO) with a cumulative return of 879.78% compared to the S&P 500's 135.94%. This translates to a massive gap of 743.84%, placing LLY at the 92.31 percentile of its historical performance relative to the S&P 500. This indicates that LLY has historically been a strong performer compared to the broader market.

**Eli Lilly and Co** is a pharmaceutical company that develops and markets a wide range of prescription drugs, including treatments for diabetes, cancer, and autoimmune diseases.

**2. Recent Price Action**

* **Closing Price:** 913.32
* **5-day Moving Average:** 920.64 
* **20-day Moving Average:** 906.92 
* **60-day Moving Average:** 896.97

LLY is currently trading slightly below its 5-day moving average, suggesting a slight short-term downward pressure. However, it remains above its 20 and 60-day moving averages, indicating a positive trend in the medium to long-term.

**3. Technical Indicators**

* **RSI:** 46.28 - This indicates that LLY is currently neither overbought nor oversold, suggesting potential for both upward and downward movement.
* **PPO:** 0.32 - A positive PPO value indicates a bullish momentum.
* **Delta_Previous_Relative_Divergence:** -0.28 - This indicates a short-term downward trend in the relative strength of LLY compared to the S&P 500.
* **Expected Return:** 36.58% - This represents the potential maximum 5-year expected return for LLY over the S&P 500, based on current investment.

**4. Recent Earnings and Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2023-05-09 | 1.96 | 8.31 B$ |

LLY's recent earnings have shown consistent growth, surpassing analyst expectations in the latest quarter (2024-08-08) with an EPS of 3.29, exceeding the anticipated 3.25. This positive earnings performance demonstrates the company's continued strong financial performance and growth trajectory. 

**5. News and Recent Issues**

**Recent Market Outlook:** 

* **FINBOLD:** Analysists are generally optimistic about LLY's future, citing strong drug pipeline and strong earnings reports.
* **Seeking Alpha:** LLY is praised for its consistent revenue growth and its strong position in the pharmaceutical market.

**Analyst Opinions:**

* **Morgan Stanley:**  Maintains an "Overweight" rating with a price target of $1,050, citing strong growth prospects for LLY's new drug launches.
* **J.P. Morgan:**  Maintains an "Overweight" rating with a price target of $1,000, highlighting LLY's robust pipeline of promising drug candidates.

**Performance Highlights:**

* LLY has seen strong performance in recent years, driven by its successful new drug launches and increasing market share.
* LLY's strong financial performance and growth potential make it an attractive investment for long-term investors.

**6. Comprehensive Analysis**

LLY has consistently outperformed the market, with a strong history of delivering robust earnings and growth. The company's focus on innovation and its deep pipeline of potential blockbuster drugs contribute to its positive outlook. The current market outlook remains positive, with analysts predicting continued growth and strong performance. While some recent technical indicators suggest a potential short-term pullback, LLY's fundamental strength and long-term growth prospects make it a compelling investment opportunity for investors seeking exposure to the healthcare sector. 
